SGLT2 Inhibitors in Heart Failure: A Class 1A Drug Regardless of Diabetes Status

A failing heart relies on two compensatory mechanisms: increased heart rate and elevated blood pressure. A beta blocker reduces both, so cardiac output falls initially and the patient feels rough — but only for the first one to two weeks. After that, sustained reduction in neurohormonal activation reverses adverse cardiac remodelling and the patient improves steadily. Always counsel patients about this dip in advance and reassure them it will get better; a heart failure nurse is an excellent resource for this kind of communication.

BNP and NT-proBNP are released in response to myocardial wall stress, so a normal BNP with a normal ECG makes acute heart failure very unlikely as the cause of a patient's breathlessness — the dyspnoea is most likely pulmonary or another non-cardiac cause. One nuance: in a patient presenting late, days after the onset of acute heart failure while partially compensating, BNP can occasionally read lower than expected, so very recent-onset context still matters.

This is congestive cardiac failure — combined right and left heart failure — and the patient should ideally be hospitalised for close monitoring of renal function and electrolytes. For NYHA class 3 or 4 patients like this, we now routinely add acetazolamide alongside loop diuretics, which improves diuresis and speeds resolution of congestion as long as renal function isn't severely impaired. If blood pressure is low, low-dose renal-dose dopamine in addition to diuretics can help significantly, particularly with right heart failure and valvular dysfunction. Given the liver cirrhosis, use a higher dose of spironolactone, since it also acts on hepatic ascites, and monitor hepatorenal function closely.

The mechanism is glycosuria, which is a nidus for genitourinary infections — balanitis in men and UTIs in women, at an incidence of around 5 to 6%. Counsel every patient on personal and perineal hygiene when starting the drug. If a genitourinary infection develops, get a urine culture, and if confirmed, hold the SGLT2 inhibitor until it resolves, then restart with reinforced hygiene counselling.

There is no substantial long-term beneficial role — it is like flogging a dead horse, a transient cardiac output boost without sustained benefit. It's useful only as a short-term emergency bridge for a profoundly hypotensive patient. We now more routinely use noradrenaline rather than dobutamine in acute low-output heart failure.

The DAPA-HF trial enrolled roughly 5,000 patients with reduced ejection fraction and followed them for about 18 months. The primary endpoint occurred in 16.3% of the dapagliflozin group compared with 21.2% on placebo, a difference large enough to yield a number needed to treat of just 21 to prevent one adverse event.

Yes. The DAPA-HF trial confirmed benefit regardless of diabetic status, which is why dapagliflozin and empagliflozin are treated as heart failure drugs in their own right rather than diabetes drugs with a cardiac side benefit. Both carry a Class 1A recommendation for all symptomatic patients with reduced ejection fraction.

SGLT2 inhibitors work by inducing glycosuria, and that sugar in the urine creates a nidus for infection: balanitis in men and urinary burning in women, occurring in roughly 5 to 6% of patients. Counselling on perineal hygiene at the time of prescribing is part of standard initiation.

No. The drug should be held until the infection resolves and then restarted with reinforced hygiene advice, rather than discontinued outright, since the cardiac benefit of remaining on therapy is substantial.